Senhwa Biosciences (ROCO:6492) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6492 Senhwa Biosciences Inc ROCO:6492
70 GF Score
Price NT$43.70
GF Value NT$46.74
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Senhwa Biosciences Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

ROCO:6492
70GF Score
Senhwa Biosciences Inc ROCO:6492
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?

Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued. The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74. GuruFocus considers Senhwa Biosciences to be Fairly Valued.

Key valuation signals for ROCO:6492:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Senhwa Biosciences Business Description

Address Peihsin Road, 10th Floor, No. 225, Section 3, Hsintien District, New Taipei City, TWN, 23143
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score

Get the complete analysis for ROCO:6492

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.70
Price
NT$46.74
GF Value